SCHEMBL24463171

SCHEMBL24463171

C#Cc1c(F)cc2c(ncn2CC)c1F

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CTSV O60911 1/20 0.33
▸ CTSL P07711 1/20 0.33
▸ CTSB P07858 1/20 0.33
▸ CTSH P09668 1/20 0.33
▸ CTSS P25774 1/20 0.33
▸ CTSK P43235 1/20 0.33
▸ CASP4 P49662 1/20 0.33
▸ MMP14 P50281 1/20 0.33
▸ CTSC P53634 1/20 0.33
▸ BACE1 P56817 1/20 0.33
▸ ADAM17 P78536 1/20 0.33
▸ CTSZ Q9UBR2 1/20 0.33
▸ KLK4 Q9Y5K2 1/20 0.33
▸ ADORA2A P29274 1/20 0.33
▸ ADORA1 P30542 1/20 0.33
▸ PI4KA P42356 1/20 0.33
▸ PI4K2B Q8TCG2 1/20 0.33
▸ PI4K2A Q9BTU6 1/20 0.33
▸ PI4KB Q9UBF8 1/20 0.33
▸ CDK1 P06493 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26790782 0.86 PTGES (0.36) CTSVCTSLCTSBCTSHCTSS
SCHEMBL24463246 0.82 CTSV (0.31) CTSVCTSLCTSBCTSHCTSS
SCHEMBL24463144 0.80 LMNA (0.33) —
SCHEMBL24463250 0.77 ADORA2A (0.35) CTSVCTSLCTSBCTSHCTSS
SCHEMBL26790558 0.75 — —
SCHEMBL26790590 0.72 FGFR1 (0.36) ADORA2AADORA1PI4KAPI4K2BPI4K2A
SCHEMBL24463425 0.72 KDM4E (0.35) CDK2
SCHEMBL26790579 0.72 GGPS1 (0.43) GGPS1FDPS
SCHEMBL26790783 0.71 NPC1 (0.31) CTSVCTSLCTSBCTSHCTSS
SCHEMBL30490088 0.69 PTGES (0.35) CTSVCTSLCTSBCTSHCTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230374015-A1 INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES KINNATE BIOPHARMA INC. 2023-11-23 — — US disclosed
US-20230374015-A1 INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES KINNATE BIOPHARMA INC. 2023-11-23 — — US disclosed
CN-116096707-A Inhibitors of fibroblast growth factor receptor kinase 金耐特生物制药公司 2023-05-09 — — CN disclosed
CN-116057045-A Fibroblast growth factor receptor kinase inhibitors 金耐特生物制药公司 2023-05-02 — — CN disclosed
EP-4161657-A1 INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES Kinnate Biopharma Inc. (US) 2023-04-12 — — EP disclosed
EP-4161656-A1 INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES Kinnate Biopharma Inc. (US) 2023-04-12 — — EP disclosed
US-11345681-B1 Inhibitors of fibroblast growth factor receptor kinases KINNATE BIOPHARMA INC. (US) 2022-05-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230374015-A1 INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES FGFR1, FGFR2, FGFR3 CTSV 1197/4885CTSL 1575/4885CTSB 1207/4885
US-11345681-B1 Inhibitors of fibroblast growth factor receptor kinases FGFR1, FGFR2, FGFR3 CTSV 1197/4885CTSL 1575/4885CTSB 1207/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback